The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | The diagnosis and management of MDS/MPN with neutrophilia (atypical CML)
Massimo Breccia, MD, Sapienza University, Rome, Italy, discusses the diagnosis and treatment of myelodysplastic and myeloproliferative neoplasms (MDS/MPN) with neutrophilia, a malignancy previously known as atypical chronic myeloid leukemia (CML). The diagnosis of this disease is assisted by next-generation sequencing (NGS), and the malignancy must be accurately distinguished from chronic myelomonocytic leukemia (CMML) and chronic neutrophilic leukemia (CNL). The prognosis of patients with this rare disease remains poor and novel therapeutic strategies must be developed. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
